Brieflands

History

The company was first founded by Seyyed M. Miri and Seyed-M Alavian as an editorial group in a Medical Institute in 2007 to publish its medical journal. After three years of experience, the number of journals increased to 5 journals, and the company launched its first form of business as a VOF (collaboration) professional STM company in Heerlen, the Netherlands, which was called "Kowsarmedical Publishing." Respecting the publishing services (from submission to publishing), especially an in-house "Journal Management System," our journals increased to more than 60 STM journals between 2010 and 2019. Since 2022, "Brieflands" is the new brand name that acts as a "Science, Technical, Medical Publisher" that publishes more than 50 journals with the services provided by 97 expert employees in three different branches.

Business Profile

  • Brieflands is a Registered Trademark with record number 1454012.
  • Brieflands has been registered as a General partnership (Vennootschap onder firma) company in the Chamber of Commerce (Kamer van Koophandel) of the Netherlands since 2010.
  • Nedmedica is our related company which is specialized in Author Services. 
  • Our former branding name was Kowsarmedical Publishing (2010-2021).
 

Communities in Brieflands

Select a community to browse its collections.

Recent Submissions

Thumbnail Image
Item
Evaluation of Mortality and Morbidity in Covid-19 Patients Treated with NIV (Non-invasive Ventilation): A 30-Day Follow-up Study
(Brieflands, 2025-04-30) Sahra Kuhkani; Fatemeh Zarghami; Neda Gilani; Farid Rashidi; Hourieh Shojaan; Leila Namvar; Sahra Kuhkani [0009-0002-2868-0602]; Fatemeh Zarghami [0000-0003-1860-1018]; Neda Gilani [0000-0002-5399-0277]; Farid Rashidi [0000-0002-7533-4334]; Hourieh Shojaan [0000-0002-8372-9926]; Leila Namvar [0000-0002-7863-0980]
Background: The COVID-19 pandemic has led to a surge in acute respiratory failure cases, necessitating effective management strategies. Non-invasive ventilation (NIV) has emerged as a treatment option; however, its efficacy and associated mortality rates remain debated. Objectives: This study aims to evaluate the mortality and morbidity rates in COVID-19 patients treated with NIV. Methods: We conducted a retrospective analysis of 50 patients diagnosed with COVID-19 [confirmed by positive nasopharyngeal polymerase chain reaction (PCR)] who received NIV at Imam Reza Hospital and Sina Medical Training Centers in Tabriz, Iran. Data were collected between April 2021 and January 2022, including demographic characteristics, clinical symptoms, laboratory findings, and outcomes, such as complications and mortality rates. For data analysis, we used logistic regression, the Mann-Whitney U test for comparing quantitative variables, and Fisher's exact test for qualitative variables. Results: Among the 50 patients, 28 (56%) died during hospitalization. The median age of non-survivors was 66 years, significantly higher than that of survivors (56 years, P = 0.018). Older age and higher Quick sepsis-related organ failure assessment (QSOFA) scores were predictive of increased mortality (OR = 1.24; P = 0.001). Additionally, complications such as pneumothorax were observed in 14% of patients. Conclusions: Our findings highlight a concerning mortality rate following NIV failure in COVID-19 patients, emphasizing the need for careful patient selection and close monitoring. Clinicians should consider early intubation for patients showing signs of NIV failure, particularly those with risk factors such as older age and high QSOFA scores.
Thumbnail Image
Item
A Rare PTF1A Enhancer Mutation Causing Neonatal Diabetes Mellitus with Pancreatic Agenesis: Case Report and Considerations for Genetic Evaluation
(Brieflands, 2025-01-31) Mahdi Paksaz; Hedieh Saneifard; Alimohammad Mirdehghan; Asieh Mosallanejad; Marjan Shakiba; Mohammad Saberi; Mahdi Paksaz [0009-0002-3441-8088]; Hedieh Saneifard [0000-0002-7926-0598]; Alimohammad Mirdehghan [0000-0001-5490-6885]; Asieh Mosallanejad [0000-0001-7926-8218]; Mohammad Saberi [0000-0001-8431-395X]
Introduction: Neonatal diabetes mellitus (NDM) is a rare disorder characterized by impaired blood glucose regulation that manifests before six months of age. Unlike autoimmune diabetes, NDM is caused by genetic mutations. One of the rarest causes of NDM is pancreatic agenesis, which results from mutations affecting the pancreas transcription factor 1A (PTF1A) gene and its enhancer. The following case report presents a rare instance of this condition. Case Presentation: This report describes a 2-year-old male child born to consanguineous Iranian parents, diagnosed with NDM due to pancreatic agenesis caused by a rare mutation in the PTF1A enhancer. Hyperglycemia was detected from the first day of life, and ultrasonography confirmed the absence of pancreatic tissue. Molecular analysis revealed homozygosity for the g.23508437A > G variant within the enhancer region of the PTF1A gene. At two years of age, with pancreatic enzyme replacement and insulin therapy, the patient exhibits normal neurological development, and his physical growth is at the 38th percentile. Conclusions: Based on previous studies, the g.23508437A > G variant in the PTF1A gene enhancer region should be considered in cases of pancreatic agenesis. While whole-exome sequencing (WES) remains the gold standard for genetic diagnosis, it may fail to detect certain mutations. Therefore, targeted evaluation of PTF1A is essential when a genetic etiology is suspected.
Thumbnail Image
Item
Enhanced Postoperative Pain Management: A Comparative Analysis of Ultrasound-Guided Quadratus Lumborum Block Versus Intraperitoneal and Periportal Bupivacaine Infiltration Following Laparoscopic Cholecystectomy: A Randomized Double-Blind Study
(Brieflands, 2025-04-30) Ashraf Nabil Saleh; Sherif F. Ibrahim; Yasmeen A. Sayed; Mohammed Mawad Alsaid A; Karim Ahmed Sedky Abdelrahman; Mohamed Mahmoud Abdelaziz Aly; Mohammed Abdulgadir Ageel; Ahmed Gamal Salah Elsawy; Mohamed Elsayed Mahmoud; Amr M. Hilal; Ashraf Nabil Saleh [0000-0002-2282-3804]; Yasmeen A. Sayed [0009-0004-4122-1149]; Ahmed Gamal Salah Elsawy [0000-0001-7075-7963]; Mohamed Elsayed Mahmoud [0009-0005-4467-3447]
Background: Inadequately managed acute pain following abdominal surgery can lead to patient discomfort, anxiety, respiratory issues, delirium, myocardial ischemia, prolonged hospital stays, and persistent pain. Objectives: This research compares the quadratus lumborum (QL) block to intraperitoneal and periportal bupivacaine infiltration for postoperative analgesia after laparoscopic cholecystectomy. Methods: This randomized double-blind study included seventy patients aged 21 to 60 years, randomly selected from Ain Shams University Hospital between March 2022 and March 2023, scheduled for elective laparoscopic cholecystectomy. The patients were divided into two groups of 35 based on postoperative pain management: Group A received intraperitoneal and periportal infiltration, while group B underwent the QL block, with details on placement and duration. Results: The results indicated a substantial decrease in Visual Analogue Scale (VAS) scores at 6 hours postoperatively, with group B exhibiting a median pain level of 3 [IQR 3 - 5] compared to group A's median of 5 [IQR 5 - 6], yielding a P-value of less than 0.001. The data indicate that group B had significantly enhanced postoperative analgesia within the initial 6 hours, both in a static condition and during movement. Moreover, patients in group B required fewer postoperative analgesics during the first 24 hours following surgery compared to group A. Conclusions: Following laparoscopic cholecystectomy, the QL block proved more effective than intraperitoneal and periportal bupivacaine infiltration in reducing postoperative pain scores for 6 hours and in reducing total opioid and analgesic use for 24 hours postoperatively.
Thumbnail Image
Item
Successful Conventional Treatment of Digoxin Toxicity Without the Administration of Digoxin-Specific Antibody Fragment: A Case Report
(Brieflands, 2025-03-22) Behzad Boushehri; Khashayar Farshid; Paniz Boushehri; Behzad Boushehri [0000-0001-5082-1470]; Khashayar Farshid [0000-0002-4298-0049]; Paniz Boushehri [0009-0009-7235-1188]
Introduction: Digoxin (Digitalis) is widely used for the treatment of various cardiac conditions. However, due to its narrow therapeutic window, toxicity can occur, necessitating hospital admission and, in severe cases, the administration of digoxin-specific antibody fragments (DSFab). Digoxin-specific antibody fragments are not readily available in the pharmaceutical market in Iran, and most patients are treated conventionally instead. Here, we present a case of severe digoxin toxicity due to an acute overdose in a suicide attempt, successfully managed without the administration of DSFab. Case Presentation: A 45-year-old Iranian female patient presenting with symptoms of altered mental status, progressing to deep coma, was admitted to Ayatollah Taleghani Hospital in Urmia, Iran. She had ingested multiple drugs, including 50 tablets of 0.25 mg digoxin, in a suicide attempt. She was diagnosed with digoxin toxicity, and treatment was initiated immediately. Laboratory data revealed a potassium level of 5.5 mEq/L and a serum digoxin concentration of 5.6 ng/mL. Electrocardiograms showed ST depression in various leads, secondary to the digoxin effect. However, no signs of bradycardia or specific arrhythmias were observed. Conclusions: Despite not receiving DSFab, the patient responded well to a carefully managed conventional treatment plan, along with continuous paraclinical evaluations and cardiac monitoring. Her condition gradually improved, leading to a successful recovery. Given the limited availability of DSFab, alternative treatment protocols demonstrate promising outcomes in the management of digoxin toxicity. Additionally, clinical symptoms, cardiac status, and electrolyte balance appear to be more crucial factors in determining the need for DSFab than the ingested dosage or serum digoxin concentration. These findings suggest that a patient-centered approach focusing on clinical stability may be more effective in guiding DSFab administration decisions.
Thumbnail Image
Item
The Role of Artificial Intelligence in Marketing Supplemental Health Insurance: A Scoping Review for Challenges and Opportunities
(Brieflands, 2024-12-31) Mohammadreza Rostami; Hossein Hosseini; Morteza Samami; Soosan Soltanmohamadi; Samira Rahmani; Hossein Hosseini [0009-0005-1309-0775]
Context: The health insurance sales network is one of the essential pillars of the health insurance industry, and redefining this role can significantly impact the performance and effectiveness of health insurance companies. The main objective of this research is to identify and analyze the challenges and opportunities involved in redefining the role of the health insurance sales network in the era of digital transformation using artificial intelligence (AI). Methodes: To explore the principles of using AI for managing the health insurance sales network, a scoping review technique was employed. A comprehensive search strategy was implemented in the PubMed, Scopus, and Google Scholar databases until the end of August 2024, using keywords related to AI, health insurance, and sales networks. The inclusion criteria encompassed peer-reviewed articles in English that focused on AI applications in health insurance sales, while the exclusion criteria involved studies not directly related to health insurance or AI. The inclusion criteria required peer-reviewed, fully identified studies with abstracts and full texts published by August 2024. The exclusion criteria included unavailable full texts, irrelevant or duplicate articles, and low-quality content. The study selection process followed PRISMA guidelines, including an initial screening of titles and abstracts, followed by a full-text review. A flow diagram illustrating the selection process is provided in the full text. Results: The results were categorized into seven main areas: The application of AI in identifying potential health insurance customers, automation of health risk assessment, targeting new health insurance products, segmentation of policyholders, predicting customer churn, estimating customer lifetime value (CLV), and predicting healthcare costs. The analysis also considered the limitations of the included studies, such as potential biases in AI algorithms and challenges related to data privacy. Conclusions: The findings indicate that AI, in addition to increasing efficiency and reducing costs, enhances relationships between health insurance companies and policyholders. Given the specific complexities of medical data and the need for personalized solutions in health insurance, AI can play a crucial role in the digital transformation of this industry. Therefore, investing in AI technologies is essential for health insurance companies to maintain leadership in today's competitive market and provide higher-quality healthcare services to policyholders.